INTRODUCTION
============

Identification of concurrent rearrangements of *MYC* (*MYC*-R), *BCL2* (*BCL2*-R), and/or *BCL6* (*BCL6*-R) is a key factor in diagnosing double-hit lymphoma (DHL) and triple-hit lymphoma (THL). These lymphomas are mainly described in the 2017 WHO Classification as high-grade B-cell lymphomas (HGBL) with *MYC*-R, *BCL2*-R, and/or *BCL6*-R \[[@b1-alm-2020-40-5-361]\]. DHL and THL (D/THL) exhibit a very low prevalence and are characterized by the presence of clinical, cytomorphological, and genetic ambiguity, especially in diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), representing a biological gray zone \[[@b1-alm-2020-40-5-361]--[@b4-alm-2020-40-5-361]\]. D/THL can also occur due to the transformation of follicular lymphoma (FL) or other low-grade B-cell lymphomas \[[@b1-alm-2020-40-5-361], [@b5-alm-2020-40-5-361]\]. The lack of an optimal treatment and the presence of aggressive clinical features, including advanced stages frequently involving the central nervous system (CNS) and poor prognosis, necessitate strategies for highly accurate diagnosis \[[@b4-alm-2020-40-5-361]--[@b9-alm-2020-40-5-361]\]. D/THL is diagnosed based on interphase FISH for *MYC*, *BCL2*, and *BCL6* (*MYC*/*BCL2*/*BCL6*) \[[@b1-alm-2020-40-5-361]\]. However, no consensus has been reached regarding the patient groups requiring additional FISH-based D/THL diagnosis, and it remains unclear whether all patients with DLBCL or aggressive B-cell lymphomas require further analysis or whether the decision should be based on immunohistochemistry (IHC) \[[@b9-alm-2020-40-5-361]--[@b15-alm-2020-40-5-361]\].

Excisional biopsies collected from lymph nodes (LN) and/or extranodal tissues are primarily used to evaluate suspected non-Hodgkin lymphoma (NHL). Bone marrow (BM) aspirates and biopsies are commonly used to stage NHL using simple antigen markers \[[@b16-alm-2020-40-5-361]--[@b19-alm-2020-40-5-361]\]. The diagnostic workup of lymphomas was performed at two different clinical laboratories, the departments of Pathology and Laboratory Medicine, at Samsung Medical Center in Korea. Ancillary tools, such as molecular and cytogenetic analyses, are used as necessary in each laboratory investigating different types of specimens. The usefulness of these ancillary tools, including flow cytometry (FCM) and cytogenetic studies, for the initial staging of NHL has been demonstrated in several studies \[[@b18-alm-2020-40-5-361]--[@b22-alm-2020-40-5-361]\]. However, many clinical laboratories do not actively conduct FCM and chromosome analysis for lymphoma diagnosis, especially with tissue specimens, because of technical and specimen limitations.

Aggressive B-cell lymphomas, particularly D/THL, show a high prevalence of BM involvement \[[@b1-alm-2020-40-5-361], [@b4-alm-2020-40-5-361]\]. Although several studies have suggested that a BM aspirate with malignant lymphoid cells is appropriate for FCM and cytogenetic analyses, there is insufficient data regarding aggressive B-cell lymphomas, particularly D/THL \[[@b1-alm-2020-40-5-361], [@b4-alm-2020-40-5-361]\]. We retrospectively investigated D/THL and their clinico-laboratory features after additional FISH analysis in BM aspirates from cases with DLBCL, BL, and B-cell lymphomas with medium to large-sized malignant lymphocytes. In addition, we present immunophenotypic and cytogenetic characteristics of D/THL, which have never been reported, especially with a focus on BM specimen.

MATERIALS AND METHODS
=====================

Patients and specimens
----------------------

We retrospectively reviewed electronic medical records, including BM reports, of 111 patients diagnosed as having BM involvement in aggressive B-cell lymphomas such as DLBCL, BL, DHL, B-cell lymphoma, unclassifiable lymphomas with features intermediate between DLBCL and BL (BCLU), and FL with large-sized and/or blastoid malignant lymphocytes from January 2000 to January 2018 at Samsung Medical Center, Seoul, Korea. The initial diagnosis revealed 86 cases of *de novo* lymphomas and 25 cases of relapsed aggressive B-cell lymphoma. Fresh BM aspirates were subjected to further workup for immunophenotyping via FCM and cytogenetic analyses including chromosome and FISH at the time of diagnosis. In 22 cases without FISH results, the BM aspirates stored as cell pellets at −70°C with median storage duration of 72 months (18--181 months) were used for FISH to confirm *MYC*-R, *BCL2*-R, and/or *BCL6*-R. At least two experts in hematopathology confirmed the agreement of the reclassification of previous pathologic diagnosis based on cytogenetic and/or FCM data. This study was approved by the Institutional Review Board of Samsung Medical Center (IRB\#-2018-01-133-001), which waived the need for informed consent.

Immunophenotypic methods
------------------------

### FCM

Sixty-seven of 111 cases were evaluated by FCM at the time of diagnosis to detect blastoid cells or atypical lymphoid cells expressing several surface markers, including CD3, CD5, CD10, CD19, CD20, and immunoglobulin (IG) kappa and lambda, using a fluorescence-activated cell sorter (FACS) Canto II (Becton-Dickinson, San Jose, CA, USA). Some of the cases, particularly those expressing lymphoblastic features, were also evaluated for immature cell markers such as CD34 and nuclear terminal deoxynucleotidyl transferase (TdT). The data were analyzed using BD FACSDiva software (Becton-Dickinson) and Kaluza software version 1.3 (Beckman Coulter, Brea, CA, USA).

### IHC

IHC was performed using nodal or extranodal formalin-fixed paraffin-embedded (FFPE) tissue biopsies prepared at the time of diagnosis. Based on the diagnosis of initial non-BM specimens, the BM biopsies were evaluated using hematoxylin and eosin staining and IHC of CD3 and CD20 antigen markers to establish malignant lymphomas. In 24 cases with cytopenia, fever of unknown origin, or suspicion of acute leukemia, the BM biopsy was used as the initial tissue specimen for a workup involving various IHC stains. The molecular subtypes were stratified according to the cell of origin (COO) based on IHC results using the Hans' algorithm \[[@b23-alm-2020-40-5-361]\]. The FFPE tissue specimens were analyzed by IHC for CD10, BCL6, and MUM1/IRF4. According to the Hans' algorithm, the DLBCL phenotype based on COO was divided into germinal center B-cell (GCB)-like (CD10+/CD10−, BCL6+, MUM1−) and non-GCB-like (CD10−, BCL-6−, or CD10-BCL6+ MUM1+) cases by semi-quantitatively scoring the fraction of tumor cells stained using a 30% threshold.

Cytogenetic studies
-------------------

Chromosome analysis was performed using heparinized, fresh BM aspirate specimens at the time of diagnosis. The specimens were cultured and harvested using standard cytogenetic methods for cancer detection. Twenty cells in metaphase were subjected to routine chromosome analysis. A complex karyotype was defined as more than three numerical and/or structural aberrations. Interphase FISH was performed on BM aspirate specimens using commercially available probes, which were previously validated to detect *MYC*-R/*BCL2*-R/*BCL6*-R. *MYC*-R was evaluated with the Locus-Specific Identifier (LSI)-*MYC* dual color break-apart (B-A) probe (Cytocell, Cambridge, UK) targeting 8q24 and/or cytocell LSI immunoglobulin heavy (*IGH*)/*MYC* dual color FISH probe detecting t(8;14)(q24;32) in all cases. In most cases, *BCL2*/*BCL6* FISH analyses were conducted depending on positive *MYC*-R results. *BCL2*-R was determined using FISH probes for the Cytocell *BCL2* dual color B-A probe to identify rearrangements in 18q21. *BCL6*-R was identified using FISH probes for Cytocell *BCL6* dual color, a B-A probe that detects rearrangements in 3q27. A total of 200 nuclei were investigated and the threshold for positivity was 2.5% for each probe. Interphase FISH was also performed using FFPE tissues with dual color B-A probes for Vysis LSI *MYC* and/or *BCL2* and/or *BCL6* (Abbott Diagnostics, Maidenhead, UK). Fifty non-overlapping nuclei were counted. A cutoff value with 3% positivity was used for each probe in the FFPE tissues.

Statistical analysis
--------------------

Chi-squared and Fisher's exact tests were used to correlate the frequencies of categorical variables between D/THL and non-D/THL groups. The Mann-Whitney test or a two-sample t-test was used to analyze continuous variables. Cohen's kappa (κ) coefficient was used to estimate the agreement between the results of chromosome and FISH analyses. Overall survival (OS) was determined from the time of initial diagnosis to death from any cause or last follow-up. The Kaplan-Meier method was used to estimate OS, and the results were compared using the log-rank test. Data were analyzed using SPSS software version 19 (IBM Corp., Armonk, NY, USA). *P*\<0.05 indicated statistically significant differences.

RESULTS
=======

Patient characteristics
-----------------------

Of the 111 patients diagnosed with aggressive B-cell lymphoma, 10 were reclassified after additional FISH analysis ([Tables 1](#t1-alm-2020-40-5-361){ref-type="table"} and [2](#t2-alm-2020-40-5-361){ref-type="table"}). One of the cases previously diagnosed as having DHL based solely on *MYC* and *BCL2* FISH was reclassified as THL after *BCL6* FISH analysis. Patient characteristics are shown in [Table 3](#t3-alm-2020-40-5-361){ref-type="table"}. Serum lactate dehydrogenase (LD) levels (reference range, 4.01--8.02 μkat/L) were significantly higher in D/THL than in non-D/THL (*P*=0.016). With a median follow-up of 22 months (0--267 months) for all patients, the median OS was significantly shorter in D/THL than in non-D/THL (*P*=0.003, log-rank *P*= 0.017). Other baseline characteristics, including sex, age, complete blood count parameters (Hb, white blood cell, and platelet counts), hemophagocytic lymphohistiocytosis of BM, and CNS involvement were not significantly associated with D/THL status.

Immunophenotypic characteristics
--------------------------------

CD5(−)/CD10(+) was significantly associated with D/THL compared with non-D/THL (*P*=0.002; [Table 3](#t3-alm-2020-40-5-361){ref-type="table"}). Other CD5(−)/CD10(+) phenotypes were expressed in eight BL, five DLBCL, and one HBCL-NOS in the non-D/THL specimens. When the COO was classified using the Hans' algorithm in 69 of our cohort cases, the GCB-like origin was not associated with D/THL (*P*=0.079). IHC staining for BCL2 (N=61), BCL6 (N=69), and Ki-67 (%, N=77) did not show significant results in distinguishing D/THL (*P*=0.559, *P*=0.355, and *P*=0.524, respectively).

Cytogenetic characteristics
---------------------------

### Chromosome and FISH analyses

Cytogenetic characteristics are shown in [Tables 3](#t3-alm-2020-40-5-361){ref-type="table"} and [4](#t4-alm-2020-40-5-361){ref-type="table"}. Of the *MYC*-R (+) cases, eight tested positive for *BCL2*-R, and three (13%, THL) tested positive for *BCL6*-R in addition to *BCL2*-R (+). A good agreement was observed between chromosomal alterations in 8q24 and *MYC* FISH (κ=0.865, *P*\<0.001). Three cases, which showed add(8)(q24.1) or add(8)(q24.2)t(8;14)(q24.1;q32.1) in chromosome analysis, were within the normal range of B-A signals or dual fusion signals in FISH (data not shown). In contrast, two of the 23 cases presented split signals only in *MYC* FISH analysis, without any aberration involving the chromosomal *MYC* region. The partner genes for *MYC*-R were inferred from the combined chromosome analysis and *MYC* FISH results ([Table 4](#t4-alm-2020-40-5-361){ref-type="table"}).

Nineteen of the 23 cases showed juxtaposition to IG loci: 15 to *IGH* (14q32), three to immunoglobulin kappa (*IGK*) (2p12), and one to immunoglobulin lambda (*IGL*) (22q11.2). Nine of the 19 cases were confirmed using the *IGH*/*MYC* FISH probe. Four of the nine cases were analyzed with both the *MYC* B-A probe and *MYC*/*IGH* dual fusion probe. *MYC*-R (+) was detected in only four cases using the *MYC*/*IGH* dual fusion probe ([Table 4](#t4-alm-2020-40-5-361){ref-type="table"}). A good agreement was observed between chromosome and FISH analyses for *BCL2*-R and *BCL6*-R, although only a small number of patients were compared (*BCL2*, N=34, κ=0.795, *P*\<0.001; *BCL6*, N=24, κ=0.833, *P*=0.002). Of the 34 *BCL2* FISH results, four showed aberrations involving the 18q21 region of the chromosome despite testing negative for *BCL2* FISH (data not shown).

### Discrepant results between different types of specimens

Evaluation of 28 of the 111 *MYC* FISH cases analyzed using FFPE tissue sections showed discrepancies across different specimens. Although a good agreement was observed (κ=0.673, *P*=0.001) when the *MYC* FISH results of the BM aspirates and FFPE tissues were compared, 14% (4/28) demonstrated discrepant *MYC* FISH results; cases 4 and 7 were *MYC*-R (+), with BM aspirates showing aberrations in the *MYC* region in the chromosome analysis ([Table 5](#t5-alm-2020-40-5-361){ref-type="table"}). In contrast, cases 55 and 67 were *MYC*-R (−), with the BM aspirates showing a normal karyotype ([Table 5](#t5-alm-2020-40-5-361){ref-type="table"}). Among these 28 cases, comparable FISH results between BM aspirate and FFPE tissue were only observed in four and two cases for *BCL2* and *BCL6* FISH, respectively. A single case (1/4, case 4) with *BCL2*-R (−) in the FFPE LN tissue, but *BCL2*-R (+) in the BM aspirate, had aberrations in *BCL2* region in the chromosome analysis ([Table 5](#t5-alm-2020-40-5-361){ref-type="table"}).

DISCUSSION
==========

Diagnosing D/THL is challenging without further FISH analysis. However, further FISH analysis in all patients with DLBCL or other aggressive B-cell lymphomas is hindered due to practical limitations \[[@b10-alm-2020-40-5-361], [@b11-alm-2020-40-5-361]\]. In this study, most patients were diagnosed histopathologically using LN or extranodal specimens before BM examination. Together with morphological findings, we confirmed two diagnostic parameters for D/THL during BM workup. First, immunophenotypic characteristics, such as CD5(−) CD10(+) combined with B-cell antigen markers, are indicators that allow for rapid screening for further FISH analysis of *MYC*/*BCL2*/*BCL6*. Second, complex karyotypes comprising chromosomal aberrations located near specific regions, such as *MYC*/*BCL2*/*BCL6* on malignant lymphocytes of the BM aspirate, strongly reflect the FISH analysis results for *MYC*/*BCL2*/*BCL6*.

CD5(−) CD10(+) phenotypes in lymphoproliferative disorders have been observed in DLBCL, BL, FL, and hairy cell leukemia \[[@b24-alm-2020-40-5-361]\]. The immunophenotypic characteristics of DHL have been defined by the expression of CD10, high expression of CD38, and frequent under-expression of CD19, CD20, and the light chain \[[@b24-alm-2020-40-5-361]--[@b28-alm-2020-40-5-361]\]. Additional diagnostic clues based on the results of chromosome analysis suggested the need for further FISH analysis in approximately 22% (24/111) of our cohort, particularly those carrying aberrations involving the 8q24 region. Chromosome analysis can facilitate the detection of D/THL in the final step of diagnosis, although cryptic translocations cannot be detected. Based on our results, the combined results of FCM and chromosome analysis can improve D/THL diagnosis and may reduce the number of cases wherein further FISH analysis is recommended. Although concurrent evaluation of *MYC*/*BCL2*/*BCL6* can rapidly reveal D/THL, many clinical laboratories use a two-step approach for their diagnostic workflow, including initial FISH for *MYC*-R followed by *BCL2*/*BCL6*-R FISH if required \[[@b7-alm-2020-40-5-361]\]. The diagnostic workflow can be determined based on a consensus between laboratory professionals and clinicians at the hospital.

Fourteen percent of our cohort showed discrepant *MYC*-R results between different types of specimens (BM aspirates and FFPE tissues; [Table 5](#t5-alm-2020-40-5-361){ref-type="table"}). Different types of specimens containing different types or numbers of malignant lymphoid cells or probe type may yield false-positive or false-negative results because of the quality of the specimens and analysis or inter-observer variation. The BM aspirate is considered as a more practical specimen than tissue specimens for FCM and chromosomal analyses, especially when suspected malignant cells are morphologically identified. Although the primary diagnosis is performed with LN or extranodal tissues (non-BM), the possibility of D/THL should also be closely investigated with BM specimens in the final diagnostic process.

A selection bias was observed in this retrospective analysis. In cases that were not fully evaluated at diagnosis, additional FISH analysis was used only in cases with available BM specimens. FCM analysis was conducted only in 67 patients at diagnosis. We did not analyze other surface markers specifically, except for CD5 and CD10, owing to the limitations of retrospective studies. Additionally, fewer specimens were analyzed compared with recent studies evaluating large cohorts for D/THL \[[@b6-alm-2020-40-5-361], [@b29-alm-2020-40-5-361]\]. The prevalence of *MYC*-R (+) cases was higher than in other studies, as our cohort included cases of BM involving aggressive B-cell lymphoma, which was related to poor prognosis in MYC-R (+) cases \[[@b29-alm-2020-40-5-361]--[@b31-alm-2020-40-5-361]\]. Second, *MYC* partner genes were not fully explored, although they have been associated with prognosis in a recent study \[[@b29-alm-2020-40-5-361]\]. The FISH probe type for identifying rearrangements was selected according to the laboratories' preference based on technical or clinical issues \[[@b32-alm-2020-40-5-361]\]. Many MYC-R cases were evaluated with the *MYC* B-A probe, while the *IGH*/*MYC* dual fusion probe was used in only a few cases. Interestingly, although four cases from our cohort were analyzed with both the *MYC* B-A probe and *MYC*/*IGH* probe, MYC-R was detected only with the *MYC*/*IGH* probe ([Table 4](#t4-alm-2020-40-5-361){ref-type="table"}). False-negative results from the *MYC* B-A probe could be generated by cryptic insertion translocation of *IGH* promoter/enhancer sequences into the *MYC* gene region \[[@b33-alm-2020-40-5-361], [@b34-alm-2020-40-5-361]\]. Therefore, some studies have suggested that both *MYC* B-A and *MYC*/*IGH* probes should be used to identify a wide range of 8q24 breakpoints that occur very close to the *MYC* gene region and that they could help detect *MYC*/non-*IGH* or non-*IG* rearrangement \[[@b33-alm-2020-40-5-361], [@b34-alm-2020-40-5-361]\]. FISH analyses for *IGK* (2p12) and *IGL* (22q11) genes were not conducted. However, the partner genes were predicted based on chromosome analysis of 19 of the 23 *MYC*-R (+) cases ([Table 4](#t4-alm-2020-40-5-361){ref-type="table"}). Many studies revealed a high prevalence of non-*IG* partners in DHL, while none of the cases showed non-*IG* partners in our five D/THL and the other 14 *MYC*-R (+) cases \[[@b35-alm-2020-40-5-361], [@b36-alm-2020-40-5-361]\]. These results might be attributed to the small cohort size.

In conclusion, a rapid and rational approach for diagnosing D/THL can be established based on CD5(−)/CD10(+) results using FCM and complex karyotypes with aberrations on *MYC*/*BCL2*/*BCL6* regions, particularly in cases of BM-involving aggressive B-cell lymphomas. Based on these results, further FISH analysis can be used effectively to establish a definitive diagnosis of D/THL among aggressive B-cell lymphomas during the BM workup.
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###### 

Re-classification based on additional FISH analysis of BM aspirates for the diagnosis of double-hit or triple-hit lymphomas

                                                         Final diagnosis[\*](#tfn2-alm-2020-40-5-361){ref-type="table-fn"}   Total                           
  ------------------------------------------------------ ------------------------------------------------------------------- ------- ------- ------- --- --- -----
  Initial diagnosis                                                                                                                                          
   DLBCL                                                 90                                                                  1       **3**                   94
   BL                                                                                                                        9       **1**   **1**           11
   DHL                                                   1                                                                                   **1**           2
   BCLU                                                                                                                                              2       2
   FL[†](#tfn3-alm-2020-40-5-361){ref-type="table-fn"}                                                                               **1**   **1**           2
                                                                                                                                                             
  Total                                                  91                                                                  10      **5**   **3**   2   0   111

Bold indicates cases reclassified as DHL or THL.

Final diagnosis was assessed with BM specimens after additional FISH analysis for the diagnosis of D/THL;

Two cases were diagnosed as having FL characterized by large-sized or blastoid malignant lymphocytes (grades 1--2 and grade 3, respectively).

Abbreviations: BM, bone marrow; DLBCL, diffuse large B-cell lymphoma; BL, Burkitt lymphoma; HGBL NOS, high-grade B-cell lymphoma, not otherwise specified; FL, follicular lymphoma; DHL, double-hit lymphoma; THL, triple-hit lymphoma; BCLU, B-cell lymphomas, unclassifiable, with features intermediate between DLBCL and BL.

###### 

Clinical and laboratory features of D/THL patients

  Case                                                  Sex   Age (yr)   LD (4.01--8.02, μkat/L)   CD5 (FCM/IHC)   CD10 (FCM/IHC)   Karyotype (BM-ASP)                                                                                                                                                                                                                                      FISH (BM-ASP/FFPE tissue)   COO (Hans')   Initial diagnosis (tissue type)   BM final diagnosis   Clinical course (OS, months)         
  ----------------------------------------------------- ----- ---------- ------------------------- --------------- ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- ------------- --------------------------------- -------------------- ------------------------------ ----- -------
  1                                                     M     62         227.12                    −/ND            +/N.D            46,XY,t(1;9)(q25;p24),dup(2)(q31q33),del(3)(q25),add(8)(q24.1)× 2,?del(14)(q32.1),der(16)t(16;17)(p13.3;q11.2),del(18)(q21.3)\[3\]/46,idem,?del(14)(q32.1)x2 \[31\]                                                                                     +/ND                        +/ND          +/ND                              ND                   BL (BM)                        THL   4.5
  2                                                     M     70         124.70                    −/ND            +/+              44,X,−Y,add(1)(q42),−2, add(4)(p12),der(5)t(1;5)(q21;q35), add(8)(q24.1),der(9)t(1;9)(q25;p21),−10,−13,add(14)(q22), add(17)(p12),add(18)(q23),+2mar \[7\]/46,XY \[10\]                                                                                 +/ND                        +/−           −/ND                              GCB                  BL (calf, soft tissue)         DHL   6.8
  3                                                     M     62         19.51                     −/ND            +/+              48,XY,der(3)t(2;3)(q31;p25)add(3)(q26.2),del(6)(q23),+7,t(8;14)(q24.1;q32),+12,t(14;18)(q32;q21.3) \[7\]/50,sl,+del(X)(q24),+10,−12,+13 \[13\]                                                                                                          +/+                         +/ND          +/ND                              GCB                  DHL (LN)                       THL   9.5
  4[\*](#tfn5-alm-2020-40-5-361){ref-type="table-fn"}   M     44         7.93                      −/−             +/+              49,XY,+del(1)(q21),der(1)del(1)(p21)add(1)(q32),del(2)(q24),der(4)t(4;18)(p16;q21.1),+7,add(8)(q24),der(8)t(8;9)(p21;q21),−9,+11, t(14;18)(q32;q21.3),+mar \[5\]/49,sl,add(17)(p13) \[3\]/49,sl,add(1)(q42),del(3)(q24),add(6)(p22) \[6\]/46,XY \[6\]   +/−                         +/−           −/ND                              non-GCB              DLBCL (LN)                     DHL   1.1
  5                                                     M     47         33.78                     −/ND            +/+              46,XY,add(1)(p36.1),t(8;14)(q24.1;q32),t(14;18)(q32;q21.3) \[8\]/47,sl,+12 \[12\]                                                                                                                                                                       +/ND                        +/ND          −/ND                              ND                   DLBCL (LN)                     DHL   0.9
  6                                                     F     71         57.03                     ND/ND           ND/+             51,X,−X,+7,+8,+8,der(8)t(8;14)(q24.1;q32)t(14;18)(q32;q21.3)× 2, +12,t(14;18),+19,+mar \[1\]/51,idem,del(12)(q13q22) \[19\]                                                                                                                             +/ND                        +/ND          −/ND                              GCB                  FL Grade 1--2 (LN)             DHL   Alive
  7                                                     M     50         245.62                    ND/−            ND/+             47,XY,t(3;4)(q27;p13),del(6)(q13),t(8;14)(q24.1;q32),t(14;18)(q32;q21.3),+21 \[10\]/48,idem,+20 \[10\]                                                                                                                                                  +/−                         +/+           +/+                               GCB                  FL Grade 2--3 (BM)             THL   Alive
  8                                                     M     77         44.97                     −/ND            +/+              50,XY,+X,t(1;14)(q42;q32),t(2;10)(q33;q24),del(4)(q21q25),+7,der(8)t(1;8)(q21;p23),+der(10)t(2;10),+12,t(14;18) \[18\]/46,XY \[2\]                                                                                                                      +/+                         +/+           −/−                               GCB                  DLBCL (thigh, soft tissue)     DHL   Alive

The case was previously diagnosed as DLBL derived from FL following treatment, and the other D/THL cases were diagnosed *de novo*.

Abbreviations: BM, bone marrow; ASP, aspirate; DLBCL, diffuse large B-cell lymphoma; F, female; M, male; LD, lactate dehydrogenase; LN, lymph node; FCM, flow cytometry; IHC, immunohistochemistry; FFPE, formalin-fixed paraffin-embedded; COO, cell of origin; GCB, germinal center B-cell, FL, follicular lymphoma; D/THL, double-hit lymphoma and triple-hit lymphoma; R, rearrangement; ND, not determined; OS, overall survival; BL, Burkitt lymphoma.

###### 

Patient characteristics by double-hit and/or triple-hit status

  Characteristics                                                       Total (N=111)          Non-D/THL (N=103)      D/THL (N=8)            *P*[\*](#tfn8-alm-2020-40-5-361){ref-type="table-fn"}
  --------------------------------------------------------------------- ---------------------- ---------------------- ---------------------- -------------------------------------------------------
  Age (range, yr), median                                               55 (1--86)             55 (1--86)             60 (44--77)            0.436
   \>60 yr                                                              48/63                  43/60                  5/3                    0.289
                                                                                                                                             
  Sex (male/female)                                                     70/41                  63/40                  7/1                    0.254
                                                                                                                                             
  CBC                                                                                                                                        
   Hb (range, g/L), median                                              107 (60--163)          107 (60--163)          107 (85--136)          0.801
   WBC (range, ×10^9^/L), median                                        6.73 (1.22--79.49)     6.60 (1.22--79.49)     7.46 (1.96--17.15)     0.873
   PLT (range, ×10^9^/L), median                                        140 (9--690)           152 (9--578)           72 (23--690)           0.576
                                                                                                                                             
  LD, median (range, μkat/L)                                            17.05 (3.96--285.04)   15.98 (3.96--285.04)   51.00 (7.93--245.12)   **0.016**
                                                                                                                                             
  HLH on BM                                                             15/96                  14/89                  1/7                    1
                                                                                                                                             
  CNS involvement (N=109)                                               30/79                  28/73                  2/6                    1
                                                                                                                                             
  Chromosome                                                                                                                                 
   Complex karyotype                                                    68/43                  60/43                  8/0                    **0.022**
    8q24 aberration[†](#tfn9-alm-2020-40-5-361){ref-type="table-fn"}    24                     17                     7                      **\<0.001**
    18q21 aberration[†](#tfn9-alm-2020-40-5-361){ref-type="table-fn"}   14                     6                      8                      **\<0.001**
    3q27 aberration[†](#tfn9-alm-2020-40-5-361){ref-type="table-fn"}    9                      3                      6                      **0.017**
                                                                                                                                             
  FCM with BM aspirates (N=67)                                                                                                               
   CD5 (−) CD10 (−)                                                     38                     38                     0                      **0.002**
   CD5 (−) CD10 (+)                                                     20                     14                     6                      
   CD5 (+) CD10 (−)                                                     8                      8                      0                      
   CD5 (+) CD10 (+)                                                     1                      1                      0                      
                                                                                                                                             
  COO                                                                                                                                        
   GCB/non-GCB (N=69)                                                   30/39                  25/38                  5/1                    0.079
                                                                                                                                             
  Ki-67 (%, N=77), Median                                               80 (5--99)             80 (5--99)             90 (60--96)            0.524
                                                                                                                                             
  OS (range, months), Median                                            22 (0--267)            20 (0--267)            7 (0--18)              **0.003**

Bold indicates statistically significant results.

Chi-square test or Fisher's exact test when appropriate;

The criteria for chromosomal aberration at appropriate cutoff points followed the "two-band rule," which only recognizes the cut points within the two-band or two-sub-bands from the target cut points at \>400-band levels.

Abbreviations: D/THL, double-hit lymphoma and triple-hit lymphoma; CBC, complete blood count; WBC, white blood cell; PLT, platelet; LD, lactate dehydrogenase; HLH, hemophagocytic lymphohistiocytosis; CNS, central nervous system; FCM, flow cytometry; BM, bone marrow; GCB, germinal center B-cell; OS, overall survival; COO, cell of origin.

###### 

Site-specific comparison of chromosome and FISH analyses results for diagnosis of D/THL in 23 *MYC*-R (+) cases with BM aspirates

  *MYC*-R (+) cases   8q24 aberration (CHR)      *MYC* partner (CHR/FISH)                                        18q21 aberration (CHR)                                            *BCL2*-R FISH   3q27 aberration (CHR)                                              *BCL6*-R FISH
  ------------------- -------------------------- --------------------------------------------------------------- ----------------------------------------------------------------- --------------- ------------------------------------------------------------------ ---------------
  1                   add(8)(q24.1)              ND/ND                                                           del(18)(q21.3)                                                    P               del(3)(q25)[\*](#tfn11-alm-2020-40-5-361){ref-type="table-fn"}     P
  2                   add(8)(q24.1)              ND/*IGH*                                                        add(18)(q23)[\*](#tfn11-alm-2020-40-5-361){ref-type="table-fn"}   P               N                                                                  N
  3                   t(8;14)(q24.1;q32)         *IGH*/*IGH*                                                     t(14;18)(q32;q21.3)                                               P               add(3)(q26.2)[\*](#tfn11-alm-2020-40-5-361){ref-type="table-fn"}   P
  4                   add(8)(q24.1)              ND/ND                                                           t(14;18)(q32;q21.3)                                               P               N                                                                  N
  5                   t(8;14)(q24.1;q32)         *IGH*/ND                                                        t(14;18)(q32;q21.3)                                               P               N                                                                  N
  6                   der(8)t(8;14)(q24.1;q32)   *IGH*/ND                                                        t(14;18)(q32;q21.3)                                               P               N                                                                  ND
  7                   t(8;14)(q24.1;q32)         *IGH*/*IGH*                                                     t(14;18)(q32;q21.3)                                               P               t(3;4)(q27;p13)                                                    P
  8                   N                          ND/ND                                                           t(14;18)(q32;q21.3)                                               P               N                                                                  N
  9                   t(8;14)(q24.1;q32)         *IGH*/ND                                                        inv(18)(p11.3q21)                                                 N               N                                                                  N
  10                  t(8;14)(q24.1;q32)         *IGH*/*IGH*                                                     N                                                                 N               N                                                                  N
  11                  t(2;8)(p12;q24.1)          2p12 (*IGK*)/ND                                                 N                                                                 N               N                                                                  N
  12                  t(8;22)(q24.1;q11.2)       22q11.2 (*IGL*)/ND                                              N                                                                 N               N                                                                  N
  13                  N                          ND/ND                                                           N                                                                 N               N                                                                  N
  14                  t(2;8)(p12;q24.1)          2p12 (*IGK*)/ND                                                 N                                                                 N               N                                                                  ND
  15                  t(2;8)(p12;q24.1)          2p12 (*IGK*)/ND                                                 N                                                                 N               N                                                                  N
  16                  t(8;14)(q24.1;q32)         *IGH*/ND                                                        N                                                                 N               N                                                                  N
  17                  t(8;14)(q24.1;q32)         *IGH*/*IGH*[†](#tfn12-alm-2020-40-5-361){ref-type="table-fn"}   t(16;18)(p13.1;q21.1)                                             N               N                                                                  N
  18                  t(8;14)(q24.1;q32)         *IGH*/ND                                                        N                                                                 N               N                                                                  N
  19                  t(8;14)(q24.1;q32)         *IGH*/ND                                                        N                                                                 N               N                                                                  ND
  20                  t(8;14)(q24.1;q32)         *IGH*/*IGH*[†](#tfn12-alm-2020-40-5-361){ref-type="table-fn"}   N                                                                 N               N                                                                  N
  21                  t(8;14)(q24.1;q11.2)       *IGH*/*IGH*[†](#tfn12-alm-2020-40-5-361){ref-type="table-fn"}   N                                                                 N               N                                                                  N
  22                  t(8;14)(q24.1;q32)         *IGH*/*IGH*[†](#tfn12-alm-2020-40-5-361){ref-type="table-fn"}   N                                                                 N               N                                                                  N
  23                  t(8;14)(q24.1;q32)         *IGH*/*IGH*                                                     N                                                                 N               N                                                                  N

The criteria for chromosomal aberration at appropriate cut points followed the "two-band rule," which only recognizes the cut points within the two bands or two sub-bands from the target cut points at \>400-band levels;

Four cases were analyzed with both the *MYC* break-apart FISH probe and *MYC*/*IGH* probe; however, *MYC* rearrangement was detected only with the *MYC*/*IGH* probe.

Abbreviations: D/THL, double-hit lymphoma and triple-hit lymphoma; R, rearrangement; BM, bone marrow; CHR, chromosome; *IGH*, immunoglobulin heavy chain; *IGK*, immunoglobulin kappa; *IGL*, immunoglobulin lambda; N, negative; P, positive; ND, not determined.

###### 

Discrepant MYC and BCL2 FISH results between BM aspirate and FFPE tissues

  Case   FISH[\*](#tfn14-alm-2020-40-5-361){ref-type="table-fn"}   FISH results   
  ------ --------------------------------------------------------- -------------- -------------------
  4      *MYC*-R/*BCL2*-R                                          P/P (DHL)      N/N (LN, DLBCL)
  7      *MYC*-R                                                   P (THL)        N (BM biopsy, FL)
  55     *MYC*-R                                                   N (DLBCL)      P (Breast, DLBCL)
  67     *MYC*-R                                                   N (DLBCL)      P (Stomach, DHL)

Dual color break-apart probes were used for *MYC*-R and *BCL2*-R.

Abbreviations: BM, bone marrow; LN, lymph node; DLBCL, diffuse large B-cell lymphoma; FFPE, formalin-fixed paraffin-embedded; FL, follicular lymphoma; DHL, double-hit lymphoma; THL, triple-hit lymphoma; N, negative; P, positive; R, rearrangement.
